Streetbeat News

BTI

British American Tobacco p.l.c.

https://www.bat.com

Industry

Tobacco

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers worldwide. It offers vapour, tobacco heating, and modern oral nicotine products; combustible products; and traditional oral products, such as snus and moist snuff. The company offers its products under the Kent, Dunhill, Lucky Strike, Pall Mall, Rothmans, Camel, Newport, Natural American Spirit, being Vapour, THP, and Modern Oral brands. It distributes its products to retail outlets. British American Tobacco p.l.c. was incorporated in 1902 and is headquartered in London, the United Kingdom.

Open

36.32

Mkt cap

81B

Volume

3.1M

High

36.70

P/E Ratio

-4.65

52-wk high

39.54

Low

36.25

Div yield

0.10

52-wk low

28.25

The FDA has granted marketing orders to R.J. Reynolds Vapor Company, a subsidiary of British American Tobacco (NYSE: BTI), for its Vuse Alto Power Unit and six tobacco-flavored pods. This decision follows an extensive scientific review and is aimed at protecting public health by providing a potentially safer alternative for adult smokers. However, the FDA has imposed stringent marketing restrictions to mitigate youth use. BTI shares are trading slightly higher in premarket trading.

Portfolio Pulse from Shivani Kumaresan

July 19, 2024 | 12:37 pm

R.J. Reynolds has received FDA marketing approval for 7 Vuse e-cigarettes, a significant regulatory milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 2:26 pm

The Supreme Court has overturned the Chevron doctrine, which required courts to defer to regulators like the FDA on certain legal issues. This decision is seen as a victory for vape manufacturers, who believe it will weaken the FDA's power to regulate tobacco and nicotine products. The FDA has been trying to ban over 1 million vapes, citing public health concerns, but vape companies now see a potential breakthrough in their legal battles.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 7:36 pm

The U.S. Supreme Court has overturned the Chevron doctrine, a 40-year-old decision that allowed the executive branch to interpret ambiguous congressional statutes. This ruling could destabilize the legal system, according to the Biden administration. Stocks of companies in the gun, tobacco, and timber industries had mixed reactions to the news.

Portfolio Pulse from Michael Juliano

June 28, 2024 | 5:25 pm

The FDA has authorized the marketing of four menthol-flavored e-cigarette products after an extensive scientific review. This decision could impact companies involved in the e-cigarette market.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 2:55 pm

Tim Seymour, portfolio manager of the Amplify Seymour Cannabis ETF (NYSE:CNBS), discusses the growth potential in the cannabis sector, emphasizing the importance of strategic partnerships, operational efficiencies, and the burgeoning U.S. hemp cannabinoid market. He highlights companies like Curaleaf, Green Thumb Industries, and Trulieve for their strong market positions and governance. Seymour also notes British Tobacco's investment in Organigram as a strategic move to expand international market reach.

Portfolio Pulse from Nicolás Jose Rodriguez

June 17, 2024 | 1:26 pm

The U.S. FDA and the Justice Department have announced the formation of a federal multi-agency task force aimed at curbing the distribution and sale of illegal e-cigarettes.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 3:27 pm

The FDA has rescinded its ban on Juul e-cigarettes due to new case law, opening the possibility for federal clearance of Juul products.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:44 pm

The FDA has rescinded its June 2022 marketing denial orders for JUUL Labs, returning JUUL's applications to pending status under FDA review. This action is prompted by new case law and additional information from JUUL. The rescission is neither an authorization nor a denial.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 1:09 pm

The FDA has raised concerns about synthetic nicotine analogues like 6-methyl nicotine, which may be more potent and addictive than traditional nicotine. These substances are not currently regulated under U.S. tobacco and vaping laws, allowing manufacturers to sell them without FDA authorization. Altria Group has highlighted the risks and urged the FDA to evaluate these compounds. Charlie's Holdings, which uses 6-methyl nicotine in its SPREE BAR vapes, is expanding its product line and targeting international markets.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 2:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.